Lung | Melanoma, skin | Other Urinary, Phase I
An Open-Label Phase 1a/1b Dose-Escalation and Expansion Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics, and Activity of AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid Tumors
Volunteers
Health Professionals
What is the purpose of this trial?
This is a phase I, First-in-Human (FIH), open-label study to evaluate the safety, tolerability, pharmacokinetic (PK) profile, and preliminary efficacy of AB248 as monotherapy OR in combination with pembrolizumab in adult participants with locally advanced or metastatic solid tumors. The study will consist of a dose escalation and a dose expansion stage.
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.
Principal Investigator
Sub-Investigators
- Anne Chiang, MD, PhD
- David Schoenfeld, MD, PhD
- David A. Braun, MD, PhD
- Emily Duffield, APRN
- Frederick Wilson, MD, PhD
- Harriet Kluger, MD
- Jeffrey Ishizuka, MD, DPhil
- John Glendening
- Marianne Davies, NP, DNP, MSN, BSN
- Michael Hurwitz, MD, PhD
- Roy S. Herbst, MD, PhD
- Sarah Goldberg, MD, MPH
- Scott Gettinger, MD
- So Yeon Kim, MD
- Thuy Tran, MD, PhD
- Vanna Dest
- Last Updated08/07/2024
- Study HIC#2000033858